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1. Introduction
Clinicians are expected to practise in accordance with 
the findings of evidence-based medicine. This implies 
that the clinician is familiar with the strongest evidence 
available. It may be difficult for the following reasons:
• The results of a given clinical trial can often only be applied to the 
specific population group and circumstances applicable to that 
specific trial. This is especially important in hormone therapy 
(HT), where initiation of therapy during the ‘therapeutic window 
of opportunity’ (between 50 and 60 years of age or within 10 years 
of onset of menopause) results in a much better benefit-to-risk 
profile than initiation in older patients.
• A small group of individuals may react to medication in a unique 
way, so studies must be adequately powered.
• Statistical significance does not always equate to clinical 
significance.
• Different methods of defining statistical significance may yield 
different answers when applied to the same data.
• Publications often only quote relative risks and ignore the clinically 
more relevant absolute risks.
• The patient’s perception is always important. For example, the 
weak association between postmenopausal HT and breast cancer 
may be of greater concern to women and the lay press than the 
stronger association between HT and thromboembolic disease.
• The side-effects of preventive medicine in healthy individuals have 
different implications to those resulting from the treatment of 
individuals with disease.
• For many years, the options for use of HT were based mainly on 
data from observational trials. Although these have generally been 
superseded by data from large randomised controlled clinical trials 
(RCTs), when considering HT the large body of observational data 
derived from women with a similar profile to that seen in everyday 
practice cannot be completely disregarded in favour of RCT data 
derived from older asymptomatic women.
• Because there are still major gaps in our knowledge, clinical 
guidelines are unable to cater for all situations.
• The final decision regarding therapy must be a joint decision 
between the healthcare provider and an informed patient, 
based on her current clinical status and ongoing new scientific 
evidence.
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• The general public is always looking for alternative medical 
treatment strategies to manage menopausal symptoms. The vast 
majority are ineffectual and some may be dangerous.
2.  Abbreviations used in this 
statement
ET = oestrogen therapy alone; EPT = oestrogen and progestogen 
therapy in combination; HT = hormone therapy, which refers to 
either ET or EPT.
3.  Position statement regarding 
menopausal HT
3.1 HT and quality of life
HT significantly improves menopause-specific quality of life (QoL), 
mainly through relief of symptoms, and especially vasomotor 
symptoms (VMSs). It may also result in a global improvement in 
sense of wellbeing. Health-related benefits depend on the severity of 
associated menopausal symptoms. Health-related and menopause-
related QoL improves more obviously in women who had significant 
menopausal symptoms before receiving HT, with considerably less 
improvement occurring in women without significant symptoms.[1]
3.2 HT and weight gain
Although weight gain associated with HT is a major concern for 
most women initiating HT, there is very little evidence to support 
this fear. There is invariably a redistribution of fat mass at the time 
of menopause, which may become apparent during the menopausal 
transition with an increase in waist-to-hip ratio. Evidence shows that 
neither ET nor EPT is responsible for an increase in weight. The 
route of hormone administration does not appear to have an impact 
on weight gain.[2]
3.3 HT and VMSs
HT remains the only treatment that consistently has a greater effect 
than placebo on alleviation of menopause-related VMSs. VMSs 
generally last 2 - 5 years, but in some individuals may last much 
longer. Patients reporting VMS for the rest of their lives are not 
rare.
 
ET is effective in relieving VMS even in low dosages, and this 
therapeutic effect is enhanced by the addition of a progestogen. 
Lifestyle-related strategies may also be of benefit.
VMSs may recur to a varying degree with cessation of HT.[3]
In clinical practice, the individual patient is the best judge of the 
effect of HT on her QoL, particularly if she is symptomatic. Routine 
monitoring of hormone levels is not advocated unless oestradiol 
implants are being used.[4-6]
In women for whom HT is contraindicated, those who decline 
treatment, or those who cannot tolerate HT, alternatives include 
selective serotonin reuptake inhibitors (SSRIs) and serotonin 
noradrenaline reuptake inhibitors (SNRIs). Although it is not 
commonly used, gabapentin has also been shown to decrease the 
occurrence of hot flushes.[7]
3.4 HT and sleep
Sleep disorders are common in the menopause and may be associated 
with VMSs, depression, anxiety, insomnia, obstructive sleep apnoea, 
fibromyalgia, restless leg syndrome, comorbid disorders or medi-
cations, or may simply be related to age. HT appears to improve sleep 
quality and quantity in menopausal women, although this has not 
been conclusively confirmed in available studies, especially where 
polysomnography has been used as an assessment tool. HT appears 
to decrease episodes of awakenings and increase rapid eye movement 
(REM) sleep by decreasing night sweats and improving mood. Further 
studies are needed to substantiate this and to determine whether type, 
dose and mode of administration impact on the quality of sleep.[8]
3.5 HT and vulvovaginal atrophy (VVA)
Systemic HT is very effective in reversing VVA. In women who have 
symptoms related to VVA alone, topical local ET only is appropriate. 
In about 15% of women using systemic HT, additional topical vaginal 
therapy is needed to achieve reversal of the atrophic symptoms. 
Vaginal creams, vaginal rings or vaginal tablets are effective options.
Local oestrogen preparations, when used correctly as sole therapy, 
do not result in sufficient systemic absorption to warrant the use 
of progestogen for endometrial protection. At present there is not 
enough evidence to mandate progestogen use in women who persist 
with any local intravaginal oestrogen preparation beyond 6 months.
Vaginal lubricants or moisturisers, with or without local oestrogen 
preparations, are also effective options.
When HT is indicated for urological symptoms, local therapy is 
preferred to systemic therapy.
Local ET improves symptoms of detrusor instability, including 
urgency, urge incontinence, frequency and nocturia, and reduces the 
incidence of recurrent urinary tract infections. Sexual function is also 
improved through the reversal of vaginal skin atrophy with increased 
vaginal lubrication.[9]
3.6 HT and menopause-associated bone loss
The increased rate of bone resorption following the onset of 
menopause clearly indicates a hormonal influence on bone density 
in women. Both transdermal and oral HT are effective in preventing 
bone loss. Supplementing with calcium and vitamin D is advisable if 
these are deficient.
HT is effective in decreasing the incidence of all osteoporosis-
related fractures. This is true for both patients at low risk of fracture 
and patients at high risk of fracture before the age of 60 years or 
within 10 years of the onset of menopause. HT decreases vertebral 
and non-vertebral fractures by approximately 50%.[3]
In some patients, a degree of fracture prevention persists after 
cessation of HT. Patients remaining at risk of fracture should receive 
ongoing therapy with proven bone-sparing medication once HT 
has been stopped. As some women lose bone rapidly after cessation 
of HT, close follow-up is needed for women not receiving ongoing 
treatment.[10]
3.7 HT and coronary heart disease (CHD)
Cardiovascular disease is the major cause of death in older women. 
Observational data have indicated that HT may reduce CHD by 
approximately 50%. This prompted several RCTs.
The following conclusions are based on an assessment of the total 
body of evidence:
3.7.1 HT does not offer secondary protection against CHD. This 
recommendation is based mainly on the data from the Heart and 
Estrogen/progestin Replacement Study (HERS), but also from data 
from the older women subset in the Women’s Health Initiative (WHI) 
study.
3.7.2 Standard-dose ET may offer primary protection against CHD 
and lower all-cause mortality in women where therapy was initiated 
during the ‘therapeutic window of opportunity’. This recommendation 
is based on data from RCTs, observational studies and meta-analyses.
The evidence that EPT in standard dosages offers primary protection 
against CHD when initiated in the window of opportunity is not 
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as consistent as the data for ET, although the effect on lowering 
mortality is the same.[3]
3.7.3 In the WHI study, an increase in non-fatal CHD was found 
in the first year of HT, but final analyses proved this to be statistically 
non-significant. It was not evident in the younger patients. It 
is therefore concluded that in women initiating therapy outside 
the ‘therapeutic window of opportunity’ who are likely to have 
established coronary artery atherosclerosis, HT is unlikely to offer 
significant protection and may cause a transient initial increase in 
adverse events.[11-16]
3.8 HT, insulin resistance and diabetes
Data suggest that combined HT reduces the incidence of diabetes in 
postmenopausal women, possibly mediated by a decrease in insulin 
resistance unrelated to body size. HT appears to reduce fasting glucose 
and fasting insulin levels, but should not be given with the primary 
intention of preventing diabetes in postmenopausal women.[17]
3.9 HT and stroke
The HERS and Women’s Estrogen for Stroke (WEST) trials, which 
were both secondary prevention studies, demonstrated a null effect 
on the combined outcome of non-fatal stroke, fatal stroke or all-
cause mortality relative to placebo in postmenopausal women 
with established cardiovascular disease. In the WHI study, a non-
significant increase in the risk of ischaemic stroke was seen in all age 
groups. The magnitude of this risk was small, however, particularly 
in patients younger than 55 years of age, where the absolute increase 
in risk was 1.5 extra ischaemic strokes per 10 000 HT users per year. 
This complication is therefore extremely rare.
A meta-analysis of observational studies has shown a non-
significant increase in the risk of overall stroke and thrombotic 
stroke (by approximately 10% and 20%, respectively). The increased 
risk of stroke associated with HT persists throughout treatment, but 
decreases after discontinuation.
Observational data suggest that lower doses of oral therapy than 
that used in the WHI will result in even less risk, and that normal and 
low-dose transdermal therapy (≤50 µg) are uncommonly associated 
with an increase in the risk of ischaemic stroke.
There is no role for HT in the primary or secondary prevention 
of stroke.[18-23]
3.10 Route of administration
Transdermal administration of HT is associated with a lower risk 
of adverse events, and particularly cardiovascular adverse events, 
than oral administration. Transdermal HT does not appear to 
increase the risk of thromboembolic disease significantly. It is 
therefore prudent to consider the transdermal route in women at 
high risk for cardiovascular events, namely obese women, smokers 
and hypertensive women, and especially if there is any history of 
thrombosis.(3)
3.11 HT and venous thromboembolism (VTE)
The relative risk of VTE increases with the use of HT. In the WHI 
study the absolute risk of VTE was increased by 18 additional cases 
per 10 000 women per year with EPT, and 7 cases per 10 000 women 
per year with ET.[24] The effect is maximal in the first year of treatment 
and decreases over time. Risk factors include obesity, previous VTE, 
underlying thrombophilia and initiation of HT after age 60 years. The 
risk of VTE in the age group 50 - 60 years is very small, but increases 
four-fold in the 60 - 69-year-old and seven-fold in the 70 - 79-year-
old age groups.[25] The route of delivery will impact on risk, with the 
highest risk being associated with oral EPT, followed by oral ET, and 
the lowest risk being associated with transdermal HT.[26,27] 
3.12 HT and breast cancer
The risk of breast cancer associated with HT in menopausal women 
is a complex issue.
Data suggest that HT may not be causal, but rather a promoter 
of pre-existing breast cancer. The absolute risk of breast cancer 
attributable to HT is low and falls into the same risk category as several 
preventable risk factors that are associated with a similar low relative 
risk for developing breast cancer. Examples of these are obesity, 
nulliparity and never having breastfed, having a first pregnancy 
after the age of 37 years and excessive alcohol intake. The increased 
risk of breast cancer is primarily associated with the addition of a 
progestogen to oestrogen therapy. In the WHI study, standard-dose 
ET was consistently associated with a lower risk of breast cancer than 
placebo, and at 12 years of follow-up this difference was statistically 
significant. Standard-dose EPT was associated with an increased risk 
of breast cancer compared with placebo. It is, however, important 
to note that on final adjudication and appropriate adjustment, this 
increase was not statistically significant. Furthermore, the increased 
risk was confined to women with prior exposure to EPT.
The increased risk of breast cancer seems to be related to the 
duration of hormone use. Observational studies show no increased 
risk for 15 - 20 years of ET use. Combined conjugated equine 
estrogen and medroxyprogesterone acetate (CEE/MPA) in the WHI 
study did not increase breast cancer risk over 7 years in new users. 
However, observational studies point to a small increased risk in 
long-term users of CEE/MPA. This effect was not seen when natural 
progesterone was used.[28-29]
The HT-related increase in breast cancer risk decreases after HT is 
stopped and disappears by about 5 years.
Breast cancer risk on HT is increased in lean women.[30-33]
3.13 HT and breast density
Higher degrees of mammographic breast density in women not 
taking HT reflect higher levels of endogenous oestrogen secretion in 
breast tissue and correlate with increased breast cancer risk.[33]
Breast density may be increased by use of ET, but this is more 
likely to occur with the use of EPT. This increased breast density may 
impede the diagnostic interpretation of mammograms. In such cases, 
cessation of EPT for 2 - 4 weeks and repeat breast image screening 
may be helpful.[34] 
If available, it would be prudent for women to undergo digital 
mammography and ultrasound. Thermal screening should be 
avoided as a diagnostic tool.
Before initiating any HT, it is recommended that the breasts are 
examined carefully and that mammographic imaging is undertaken 
and followed conventionally thereafter.
3.14 HT and risk of other cancers
3.14.1 Colorectal cancer
There is continuing evidence that oral HT results in an approximately 
40% reduction in the incidence of colorectal cancer, and that this 
benefit is more pronounced in the EPT group.
However, HT is not indicated for primary prevention of colorectal 
cancer.[35,36]
3.14.2 Endometrial cancer
Oestrogen-only therapy should not be prescribed for women 
with an intact uterus, who should always receive a progestogen 
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simultaneously. The primary indication for progestogen use in 
women on HT is endometrial protection. Combined EPT should not 
be prescribed for women who have had a hysterectomy, unless they 
have a history of extensive endometriosis.
Long-term use of continuous combined EPT offers superior 
protection of the endometrium compared with sequential regimens 
and hence reduces the risk of endometrial cancer significantly more 
than sequential HT. The maximum duration of sequential HT should 
not exceed 5 years, after which continuous combined EPT should be 
prescribed. Long-term cycle regimens with 3-monthly withdrawal 
bleeds are not recommended.[37,38]
The levonorgestrel intrauterine system plus ET is comparable to 
other progestogen regimens.
3.14.3 Ovarian cancer
There are as many studies showing an increased risk of epithelial 
cancer as there are studies showing a null effect or a negative effect 
in HT users compared with non-users. The risk is so small that it is 
unlikely to influence prescribing habits.[39,40]
3.14.4 Lung cancer
Although combined HT does not significantly increase the inci dence 
of lung cancer, it does increase death from lung cancer, and the risk 
continues after cessation of therapy. This should be of concern to 
users of HT who are smokers or have other risk factors for lung 
cancer.[41]
3.15 HT in breast and gynaecological cancer survivors
3.15.1 Breast cancer survivors
At present, it is prudent not to offer HT routinely to breast cancer 
survivors for management of menopausal symptoms, even though 
the  data are somewhat controversial. Three randomised trials have 
addressed this issue, two of which showed an increase in cancer 
recurrences, while the other did not. None of the three studies 
showed an increase in death from the disease.[42-44]
Data derived from observational studies, including two large meta-
analyses, do not show an increase in recurrences or death rate in 
breast cancer survivors using HT.
HT should be prescribed only when patients are fully informed of 
the current available data and wish to use this therapeutic modality.
There is no evidence to suggest that transvaginal topical oestrogen 
increases recurrence, so it may be prescribed to patients with 
intractable symptoms associated with urogenital atrophy.[45]
3.15.2 Gynaecological cancer survivors
HT for the management of VMS is not contraindicated in survivors 
of vulval, vaginal or cervical cancer.
However, in survivors of endometrial or ovarian cancer, even 
though the data are controversial with many studies finding no detri-
mental effect of HT, it is prudent not to administer HT routinely.[46]
3.16 Alzheimer’s disease (AD) and cognition
There is observational evidence that HT initiated during the 
‘therapeutic window of opportunity’ may be protective against AD 
in later life. However, HT used after the age of 65 years carries an 
increased risk of all-cause dementia, which is more prevalent with 
EPT than with ET.
HT is not indicated for the prevention or treatment of AD.
Short-term memory dysfunction is common in the menopausal 
transition and is usually self-limiting. HT appears to benefit this 
dysfunction.[47,48]
3.17  Primary ovarian insuciency (POI) (premature 
menopause)
POI refers to ovarian failure with at least 4 months of amenorrhoea 
and follicle-stimulating hormone levels in the menopausal range on 
two occasions within a 4 - 6-week interval, in women younger than 
40 years of age. The principles of treatment that apply to women 
undergoing a natural menopause at ~51 years are not applicable to 
young women with POI.
Data from studies of women with POI show decreased survival, 
increased cardiovascular risk, increased risk of fracture, sexual dys-
function and possibly increased cognitive dementia and Parkinson’s 
disease. HT will decrease these risks, alleviate symptoms and preserve 
bone density, especially after bilateral oophorectomy.[49-51]
It is recommended that HT or oral contraception be used at least 
until the natural age of menopause. For younger women, higher doses 
are often needed to control symptoms.[52]
3.18 Androgen therapy
Hypoactive sexual desire disorder (HSDD) is the commonest sexual 
dysfunction in the climacteric. Testosterone levels in women decline 
as a result of ageing, but not to the extent of the precipitous decline 
demonstrated by oestrogen in menopause. The reduced levels of 
testosterone in postmenopausal women are associated with loss of 
libido, decreased sexual activity, diminished feelings of wellbeing and 
fatigue. Testosterone is an effective treatment for HSDD in women 
receiving concomitant ET. Testosterone on its own is not advocated.
Other conditions in which androgen levels are low and in which 
HSDD is likely to occur include POI, surgical menopause, adrenal 
insufficiency and hypopituitarism. These women are also candidates 
for testosterone therapy.[53-55]
There are currently no female testosterone therapies registered or 
available in South Africa (SA). Tibolone, which has weak androgenic, 
oestrogenic and progestogenic activity and does not increase 
sex hormone binding globulin, can be used as an alternative to 
testosterone.[56]
3.19 Targets beyond the obvious
Evidence is accumulating to support the beneficial effects of HT on 
the skin and, to a certain extent, on the oral cavity.[57,58]
3.20 New combinations and HT preparations
The new third-generation selective oestrogen receptor modulators 
and oestrogen combination preparations have a favourable impact 
on breast tissue and will be used more frequently to treat menopausal 
symptoms and osteoporosis.
• Bazedoxifene with conjugated oestrogens is such a preparation.
• Ospemifene, a new oral oestrogen receptor modulator, has been 
shown to be effective in reversing the symptoms associated with 
vulvovaginal atrophy, dyspareunia in particular.
3.21 Bioidentical HT (BHT) for menopausal symptoms
BHT is the use of hormones identical to those secreted in the ovary 
or adrenal gland, namely oestradiol, oestrone, oestriol, dehydro-
epiandrosterone (DHEA) and testosterone.[59] These are frequently 
compounded for specific patients in compounding pharmacies. 
The Federal Drug Administration reported a study of compounded 
pharmaceutical products that found significant aberrations with 
regard to quality and potency of these products.[60] In SA, conventional 
HT products require mandatory regulation and registration by the 
Medicines Control Council. This involves regular testing for purity, 
potency, efficacy and safety. Bioidentical hormone and compounding 
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products require no such regulation. There is no evidence to 
support claims of greater efficacy or safety for BHT compared 
with conventional HT. The addition of oestriol to oestradiol with 
or without oestrone does not significantly alter the oestrogenic 
content of the oestrogen compound and certainly does not reduce 
the risk of breast cancer as is claimed. The absorption of bioidentical 
progesterone cream is variable, unpredictable and unreliable, and 
its use for opposing the effects of oestrogen on the endometrium is 
therefore not recommended.[61,62]
There are no long-term safety studies for BHT, and no procedures 
exist for reporting adverse events. The use of BHT is not recommended.
3.22  Complementary and alternative medicines (CAMs) 
and menopausal symptoms
• CAMs are remedies not recognised in conventional medicine. 
They have become popular because of the mistaken belief that 
‘natural’ medicines have no adverse effect. The term ‘natural’ gives 
a subliminal message of safety. There is no such thing as natural 
medicine. All medicinal products are manufactured in factories.
•  Phyto-oestrogens are mainly sourced from soy and red clover, 
which express their pharmacological action through isoflavones. 
Most studies have shown a null effect or at most a minimal effect 
on VMSs in comparison with placebo.[63]
• Isoflavones appear to have no serious side-effects, although if high 
doses are used for long periods of time, they may stimulate the 
endometrium and breast.
• Black cohosh has no phyto-oestrogenic activity and is thought to 
have serotonin agonist properties. It appears to have poor efficacy 
for menopausal symptoms.[64]
•  Black cohosh has been shown to be hepatotoxic.
• Both isoflavones and black cohosh should be avoided in women 
being treated for breast cancer.[65] Genistein (an isoflavone) may 
negate the inhibitory effect of tamoxifen on breast tumour growth.[66]
4. Clinical guidelines
• The menopausal transition should be utilised as a window of 
opportunity to assess and manage specific as well as general 
health-related matters. A medical history should be taken and 
general breast and gynaecological examinations, including cervical 
cytology, should be done.
• Special investigations should include a fasting lipogram, blood 
glucose measurement, mammography, thyroid function testing and, 
for patients considered to be at risk of osteoporosis, measurement of 
bone density by dual-energy X-ray absorptiometry. Investigations 
for hypercoagulable states before instituting HT are only required 
in patients at risk (personal or family history of VTE).
• Lifestyle modifications such as cessation of smoking, adjustment of 
diet, maintenance of an appropriate body mass index, exercise and 
stress control should be discussed.
• Treatment of dyslipidaemias, hypertension, diabetes and other 
medical conditions must be optimised.
• HT should only be initiated for specific proven indications, 
provided there are no contraindications, and should be 
individualised according to each patient’s needs. Women need to 
be fully informed of all risks and benefits regarding HT.
4.1 Indications for HT
• Treatment of VMSs and associated sleep disorders
• Symptomatic urogenital atrophy
• Prevention of bone loss in women with premature menopause or 
secondary amenorrhoea, and in women with osteopenia who are 
at risk of fracture.
• Treatment of osteoporosis in women in the age group 50 - 60 years 
and at risk of fracture, with or without VMSs.
4.2 Contraindications
HT should generally not be prescribed in the following circumstances:
• Current, past or suspected breast cancer
• Known or suspected oestrogen-dependent malignant tumours
• Undiagnosed genital bleeding
• Untreated endometrial hyperplasia
• Previous idiopathic or current VTE
• Known arterial CHD
• Active liver disease
• Porphyria cutanea tarda
• Thrombophilia.
4.3 General guidelines
• The duration of HT should be based on the indication for 
treatment.
• The indication for therapy should be reviewed on an annual 
basis. The decision whether to continue treatment for the relief of 
climacteric symptoms may be made by temporarily discontinuing 
treatment. If symptoms do not recur, HT does not have to be 
resumed. Topical therapy for relief of urogenital atrophy symptoms 
may need to be continued long-term.
• Only long-term therapy is effective for the prevention or treatment 
of osteoporosis. Long-term HT may be considered for bone effects, 
weighing benefit and risks against those of alternative therapies. 
At present there is no compelling evidence to restrict duration of 
treatment as long as treatment goals are maintained.
• HT should ideally be commenced during the ‘therapeutic window 
of opportunity’, especially if therapy is to maximise the beneficial 
impact on the cardiovascular system and the brain.
• Systemic HT should not be initiated in women older than 60 years 
of age.
• All oestrogens and progestogen formulations, including tibolone, 
should be considered similar in terms of clinical risks and benefits.
• These statements are applicable to all routes of administration, 
including transdermal application. The non-oral route avoids 
the first-pass effect in the liver and is preferable in women with 
hypertriglyceridaemia, liver disease, migraine, glucose intolerance 
and an increased risk of VTE, and in those who are smokers.
• Should EPT be required for longer than 5 years, it is recommended 
to convert from sequential HT to continuous combined HT.
• Low-dose therapy has been shown to be effective in symptom 
control and for prevention of bone loss; the principle of the lowest 
effective dose should therefore be adhered to.
• Low-dose and ultra-low-dose oestrogen preparations have fewer 
adverse effects than standard-dose therapy.
• Women with a history of stroke or transient ischaemic attack 
should be discouraged from initiating HT.
• Prior to commencing HT, all patients should be advised to 
undergo breast screening, including digital mammography (where 
available) and ultrasound examination. Ideally all menopausal 
women should have regular mammography.
• Abnormal bleeding is quite common in the first 6 months of using 
continuous combined HT, especially if the patient is less than 1 year 
post menopause. If abnormal bleeding or spotting persists for more 
than 6 months after initiating the HT, endometrial surveillance 
in the form of an endometrial sampler, determining endometrial 
thickness by saline hysterography, direct hysteroscopic assessment 
and biopsy, or a formal diagnostic dilatation and curettage should 
be considered.
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• The use of bioidentical HT is not recommended. Studies on 
phyto-oestrogens and botanicals have shown inconsistent results. 
Most good studies show no clear benefit and some potential 
for harm. Further research is required in order to make firm 
recommendations.
• No published data exist on the use of traditional African medicines 
for menopausal symptoms.
• No therapy for menopausal symptoms should be initiated 
without proper clinical assessment, including breast and pelvic 
examination.
• If HT is contraindicated or not tolerated, effective alternatives for 
VMSs include SSRIs, SNRIs and gabapentin.
• Provided there are no contraindications, HT can be administered 
for more than 5 years. Once the decision has been taken to 
discontinue HT, the dose can be tapered over time before it is 
stopped totally.
• These statements are applicable to all routes of administration.
5. Conclusion
In order to assist the patient in making informed decisions about her 
menopausal management, every practitioner needs to be aware of the 
latest evidence regarding HT. It is anticipated that HT in conjunction 
with lifestyle modifications will remain the treatment of choice for 
acute menopausal symptoms for the immediate future. It is to be 
hoped that ongoing research will be able to identify a patient profile 
or method of application where longer use of HT is without risk. This 
will unlock the true potential of HT in the prevention and treatment 
of osteoporosis and allow new understanding of its role in the 
primary prevention of cardiovascular disease. Oestrogen receptors 
are ubiquitous in women. Consequently, even though HT impacts 
most positively on the management of acute menopausal symptoms, 
if used from the ‘window of opportunity’ its global benefits extend to 
a wide number of other organs, especially the cardiovascular system, 
skeletal system and brain. Provided the patient has no untoward 
complications and continues to be monitored appropriately, we 
believe that HT can be prescribed for long-term use, and need not be 
routinely stopped within 5 years or by age 65 years.
Concern about HT was accelerated by the WHI studies. Many 
of those data have since been reinterpreted and revisited. This is 
an ongoing process that may result in this position statement being 
reviewed and updated again in the future.
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